SCHEMBL3373733

SCHEMBL3373733

CC(C)c1nnc(NS(=O)(=O)c2ccc(C3(C(N)=O)CCC3)cc2)s1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.56
HSD17B10 Q99714 2/20 0.56
KMT2A Q03164 1/20 0.42
LMNA P02545 2/20 0.41
CA1 P00915 5/20 0.40
CA2 P00918 5/20 0.40
CA9 Q16790 2/20 0.40
HPGD P15428 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GAA P10253 1/20 0.39
AKT1 P31749 2/20 0.39
PKM P14618 1/20 0.38
CA12 O43570 1/20 0.38
CA3 P07451 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373738 0.82 ALDH1A1 (0.57) ALDH1A1HSD17B10KMT2ALMNACA1
SCHEMBL13068607 0.79 ALDH1A1 (0.56) ALDH1A1HSD17B10KMT2ALMNACA1
Hydrochloric Acid SCHEMBL3373803 0.78 ALDH1A1 (0.55) ALDH1A1HSD17B10KMT2ALMNACA1
SCHEMBL3372765 0.77 ALDH1A1 (0.51) ALDH1A1HSD17B10KMT2ALMNACA1
SCHEMBL3788760 0.77 ALDH1A1 (0.61) ALDH1A1HSD17B10KMT2ALMNACA1
Glyprothiazol SCHEMBL1814714 0.76 ALDH1A1 (0.71) ALDH1A1HSD17B10LMNACA1CA2
SCHEMBL5398574 0.75 ALDH1A1 (0.73) ALDH1A1HSD17B10KMT2ALMNACA1
SCHEMBL5401314 0.74 ALDH1A1 (0.71) ALDH1A1HSD17B10KMT2ALMNACA1
SCHEMBL5404610 0.74 ALDH1A1 (0.71) ALDH1A1HSD17B10KMT2ALMNACA1
SCHEMBL5388827 0.74 ALDH1A1 (0.71) ALDH1A1HSD17B10KMT2ALMNACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937659-B1 CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2010-11-10 EP disclosed
US-7683181-B2 Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof SANOFI-AVENTIS (FR) 2010-03-23 US disclosed
US-20080280959-A1 CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2008-11-13 US disclosed
EP-1937659-A1 CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-07-02 EP disclosed
WO-2007039173-A1 CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280959-A1 CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF PPARD, GPR119, PPARG ALDH1A1 1628/4885HSD17B10 1246/4885KMT2A 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.